(BNKL) – Business Wire
-
Bionik Laboratories Expands Its Partnership With Lifepoint Health With the Installation of InMotion® Robotic Devices at Four New Locations
-
Bionik Laboratories Reports a Significant Increase in Patient Volume at Its Acquired Rehabilitation Center in Florida
-
Bionik Laboratories Enters into Distribution Agreement with Pro-Med Technology for the Sale of InMotion® Robotic Devices in Hong Kong
-
Bionik Laboratories’ InMotion® Robotic Devices on Display at the Korea International Medical & Hospital Equipment Show (KIMES)
-
Bionik Laboratories Reports Third Quarter Fiscal Year 2023 Financial Results
-
Bionik Laboratories Reports Second Quarter Fiscal Year 2023 Financial Results
-
Bionik Laboratories Appoints Richard Russo, Jr. as Chief Executive Officer and Dan Gonsalves as Chief Financial Officer
-
Bionik Laboratories Acquires Florida Rehabilitation Center; First in Strategic National Rollout
-
BIONIK Laboratories Reports First Quarter Financial Results
-
BIONIK Laboratories Corp. to Present at Investor Summit Group’s Q3 Virtual Conference
-
BIONIK Laboratories Announces the Sale & Installation of a New InMotion® ARM/HAND Robotic Device to Tampa General Hospital for its Rehabilitation Center
-
BIONIK Laboratories Reports Fourth Quarter and Fiscal Year 2022 Financial Results
-
BIONIK Laboratories to Attend the 2022 American Occupational Therapy Association (AOTA) Conference & Expo
-
BIONIK Laboratories Reports 15-20% Increase in Therapeutic Gains on InMotion® Robotic Devices in New Patient Outcomes Data Report
-
BIONIK Laboratories Reports Third Quarter Fiscal Year 2022 Financial Results
-
BIONIK Laboratories to Participate at the American Physical Therapy Association Conference
-
BIONIK Laboratories to Participate at MEDICA, a Leading International Trade Show for the Medical Industry
-
BIONIK Laboratories Reports Second Quarter Fiscal Year 2022 Financial Results
-
BIONIK Laboratories Announces Commercial Team Addition With Newly Hired Regional Sales Director, Tony Bellofatto
-
BIONIK Laboratories Reports a 72% Increase in Patient Sessions on its InMotion® Robotic Devices Since Launch of InMotion Connect™ Platform
-
BIONIK Laboratories Reports Fiscal 2022 Q1 Financial Results
-
BIONIK Laboratories Announces $5 Million Capital Raise through Issuance of Convertible Notes
-
BIONIK Laboratories Announces Resignation of CEO, Names Interim CEO
-
BIONIK Laboratories Reports Fiscal 2021 Financial Results
-
BIONIK Laboratories Reports Fiscal 2021 Q3 Financial Results
-
BIONIK Laboratories Corp. Appoints Rich Russo, Jr. as CFO
-
BIONIK Laboratories Announces Fiscal 2021 Q2 Financial Results
-
BIONIK Laboratories Announces Sale of New InMotion® ARM/HAND Robotic Device to VA Rehabilitation Research & Development’s Center for Neurorestoration and Neurotechnology
-
BIONIK Laboratories Announces Fiscal 2021 Q1 Financial Results
-
BIONIK Laboratories Announces Fiscal 2020 Financial Results
-
BIONIK Laboratories Launches InMotion Connect™, Driving Outcomes through Internet of Things (IoT) and Intelligent Data
-
BIONIK Laboratories Donates InMotion® Robotic System to Einstein Healthcare Network’s MossRehab for Use in New COVID-19 Rehab Unit
-
BIONIK Laboratories Announces Third Quarter Fiscal 2020 Financial Results
-
BIONIK Laboratories Announces Regulatory Approval and First Sale of its InMotion® ARM Robotic Technology by its Exclusive Distributor in South Korea
-
BIONIK Laboratories Selects Propel to Accelerate New Product Development and Manufacturing of InMotion Robotic Systems and Services
-
BIONIK Laboratories Announces Second Quarter Fiscal 2020 Financial Results
-
BIONIK Laboratories Partners with Intelliware Development to Provide Seamless Connectivity Between InMotionTM Robotic Devices and Hospital Information Systems
-
BIONIK Laboratories Appoints Loren Wass as Chief Commercial Officer
-
BIONIK Laboratories’ Fiscal Year 2020 Q1 Financial Results Feature 57% Increase in Sales
Back to BNKL Stock Lookup
